Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Beigene Ltd Ads (BGNE)

Beigene Ltd Ads (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
111 Unveils New Video on The Impact of Chinese Policies to Medical Industry

111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced the release of the sixth episode in its 111 Insight series. The title announced today,...

BGNE : 170.36 (+1.50%)
YI : 6.63 (+1.53%)
111 Unveils New Video on the Impact of the Internet and other New Technologies on the Medical Industry

111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced the release of the fifth episode in its 111 Insight series. The title announced today,...

BGNE : 170.36 (+1.50%)
YI : 6.63 (+1.53%)
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT(R) and QARZIBA(R) in Greater China

- SYLVANT and QARZIBA recently listed for fast-track approval in China -

BGNE : 170.36 (+1.50%)
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
JPM : 138.20 (+0.69%)
Leap Therapeutics Surges on License Agreement With BieGene

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

MRK : 90.97 (-0.23%)
BMY : 66.72 (-0.09%)
BGNE : 170.36 (+1.50%)
LPTX : 1.78 (+14.10%)
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company...

BGNE : 170.36 (+1.50%)
LPTX : 1.78 (+14.10%)
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

-- Anthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors

BGNE : 170.36 (+1.50%)
AMGN : 241.49 (+0.41%)
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

BMY : 66.72 (-0.09%)
BGNE : 170.36 (+1.50%)
INVA : 14.43 (-0.55%)
GH : 84.60 (+1.50%)
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene...

BGNE : 170.36 (+1.50%)
China National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Classical Hodgkin's Lymphoma Who Have Received at Least Two Prior Therapies

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID(R) in Relapsed or Refractory Indolent Lymphoma

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
CELGZ : 0.47 (+2.15%)
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenstrom's Macroglobulinemia

- Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)

BGNE : 170.36 (+1.50%)
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
MRTX : 97.05 (-0.39%)
BeiGene Announces Clinical Data on BRUKINSA(TM) (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma

BGNE : 170.36 (+1.50%)
BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene...

BGNE : 170.36 (+1.50%)
BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 170.36 (+1.50%)
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients...

BGNE : 170.36 (+1.50%)
ZYME : 49.12 (+11.36%)
U.S. FDA Grants BeiGene's BRUKINSA(TM) (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

- This marks the first FDA approval for BeiGene

BGNE : 170.36 (+1.50%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE

Pomerantz LLP is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

BGNE : 170.36 (+1.50%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar